IMPORTANT SAFETY INFORMATION
OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation
solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to
acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs
(NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at 2-24% are eye irritation, posterior
capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Use of OMIDRIA in children has not been established.
INDICATIONS AND USAGE
OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular
lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis
and reducing postoperative ocular pain.
Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2016.
Please see the Full Prescribing Information at
www.omidria.com/prescribinginformation.
* Individual insurance coverage and policies may vary, and Omeros does not guarantee
insurance coverage or payment. Omeros offers payments under the OMIDRIAssure
"We Pay the Difference" program on behalf of qualifying patients. OMIDRIAssure
is subject to change without notice.
Visit www.omidria.com
OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, and
OMIDRIAssure® are registered trademarks of Omeros Corporation.
© Omeros Corporation 2017, all rights reserved. 2017-007
• Preempt miosis and inhibit
postoperative pain
1
• Block the surgically induced
inflammatory cascade with the
first and only NSAID FDA-approved
for intracameral use
1
• Eliminate the risks and liabilities
of compounded products
by using FDA-approved,
GMP-manufactured OMIDRIA
•
Avoid reimbursement difficulties
by using broadly covered OMIDRIA
and the OMIDRIAssure
®
services
(OMIDRIAssure.com)*
CHOOSE OMIDRIA FOR YOUR NEXT CATARACT SURGERY PATIENT
THE POWER OF PREEMPTION
OMIDRIA
®
is the first and only
FDA-approved drug that provides
continuous intracameral delivery
of
NSAID and mydriatic/anti-miotic
therapy during cataract surgery
1
LEARN MORE AT
ASCRS BOOTH #1915
